Onderneming Kancera AB (publ) Nasdaq Stockholm
Aandelen
SE0015658570
Biotechnologie & Medisch Onderzoek
Vakgebied
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Selin
CEO | Chief Executive Officer | - | 01-03-22 |
Director of Finance/CFO | 75 | - | |
Johan Schultz
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-13 |
Martin Norin
COO | Chief Operating Officer | 65 | 01-01-10 |
Thomas Olin
CTO | Chief Tech/Sci/R&D Officer | 66 | 05-05-10 |
Markus Jerling
CTO | Chief Tech/Sci/R&D Officer | 72 | 01-09-23 |
Niclas Brynne
PRN | Corporate Officer/Principal | 63 | 01-09-16 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 63 | 05-05-10 | |
Director/Board Member | 66 | 01-01-16 | |
Håkan Mellstedt
FOU | Founder | 82 | 28-04-10 |
Thomas Olin
CTO | Chief Tech/Sci/R&D Officer | 66 | 05-05-10 |
Director/Board Member | 72 | 28-05-12 | |
Director/Board Member | 58 | 30-05-18 | |
Petter Brodin
BRD | Director/Board Member | - | 26-05-21 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 121 186 228 | 55 214 243 ( 45,56 %) | 0 | 45,56 % |
Bedrijfsgegevens
Kancera AB
Karolinska Institutet Science Park Nanna Svartz Väg 4
171 65, Solna
+46 8 50 12 60 80
http://www.kancera.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,82% | 121 mld. | |
+20,35% | 113 mld. | |
+17,47% | 26,02 mld. | |
-25,31% | 19,39 mld. | |
-19,51% | 15,91 mld. | |
-19,67% | 15,09 mld. | |
-46,87% | 15,06 mld. | |
+62,55% | 14,93 mld. | |
+6,34% | 13,85 mld. |